Cybin Inc.
HMNC Brain Health and Develco Pharma have announced promising top-line results from the Phase II proof-of-concept investigator-initiated trial of its oral prolonged-release formulation of ketamine (KET01)...
New research has suggested that sub-anaesthetic doses of ketamine could be beneficial for conditions such as post-traumatic stress disorder (PTSD), anxiety, addiction and eating disorders.
Field Trip Health is partnering with online mental health platform, Cerebral, to provide improved mental health care.
Psychedelic-assisted psychotherapy is being investigated by Novamind to help people with difficult-to-treat indications and who are historically underserved.
Some patients hospitalised with severe suicidal thoughts could benefit from ketamine treatment.
A review has shown that ketamine therapy is able to rapidly reduce symptoms of depression and suicidal thoughts in the short-term.
The groundbreaking study will now be expanded to explore the use of ketamine for treating binge eating disorder, compulsive sexual behaviour and internet gaming disorder.
Co-founder and CEO Anthony Tennyson spoke to Psychedelic Health about Awakn’s mission to transform mental health and addiction care through psychedelics.
With the “one-size-fits-all” approach being the norm in the psychiatric industry, HMNC Brain Health is aiming to shake this up through targeted and personalised therapies powered...